SecBot SecBot

VXRT

Vaxart, Inc.
OTC· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000072444 Biotech & Drug Discovery
$0.3600 −0.01 (−2.70%)
Nov 16 4:00 PM ET · prev $0.3700
Median target
$4.00
+1011% · range $2.00–4.00
1 year
−7.7%
from $0.3900 · Nov 17
30 days
−25.0%
from $0.4800
52-week range
$0.3500–0.8000
−55% from high · low Nov 25
Avg volume 20D
282.7K
shares / day
Short interest
2.42M
+0.5%
Days to cover
4.0
at average volume
Insider net
+$6.5K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q3 2025 13F · 0 exits
Filing reports
21
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $6.5K at an average $0.6530. No open-market sales. Price is 45% below their cost.

  • InstitutionsMIXED

    Q3 2025: 1 added (0 new), 0 trimmed or exited.

  • Short sellersSTEADY

    Short interest +0.5% to 2.42M shares. 4.0 days to cover.

  • TrendDOWNTREND

    18% below its 50-day average.

Who's buying

13F· Q3 2025
0
new positions
0
exits
FundMoveSharesValue
SIMPLEX TRADING, LLCADD18,592$6.0K
UBS Group AGADD825,758$373.2K
Squarepoint Ops LLCTRIM446,852$202.0K
ROYAL BANK OF CANADADOUBLED223,866$101.0K
TWO SIGMA INVESTMENTS, LPDOUBLED106,929$48.3K
GOLDMAN SACHS GROUP INCADD97,407$44.0K
Sequoia Financial Advisors, LLCTRIM37,000$16.7K
HighTower Advisors, LLCTRIM17,051$7.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Mar 2025
12-month targets · 3 analysts

Price is below the lowest target. Median implies +1011%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Mar 27, 2025B. Riley Securities
MAINTAIN
MAINTAINBuy
Aug 15, 2024Oppenheimer
INITIATE
INITIATEOutperform
Jan 31, 2024B. Riley Securities
UPGRADE
UPGRADEBuy
Sep 7, 2023Cantor Fitzgerald
REITERATE
REITERATEOverweight
Aug 7, 2023Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Dec 19, 2022B. Riley Securities
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$6.5K
bought · 1 insider
$0
sold · 0 insiders
−44.9%
vs their $0.6530 cost
DateInsiderTypeValue
Oct 16, 2026
Bono Raquel C.
Director
Oct 16, 2026
AWARD78,800 sh
Oct 16, 2026
Bono Raquel C.
Director
Oct 16, 2026
AWARD157,400 sh
Jul 16, 2026
HERON ELAINE J
Director
Jul 16, 2026
AWARD78,700 sh
Jul 16, 2026
BREITMEYER JAMES B
Director
Jul 16, 2026
AWARD8,315 sh
Jul 16, 2026
HERON ELAINE J
Director
Jul 16, 2026
AWARD39,400 sh
Jul 16, 2026
Wheadon David E.
Director
Jul 16, 2026
AWARD39,400 sh
Jul 16, 2026
Watson W. Mark
Director
Jul 16, 2026
AWARD78,700 sh
Jul 16, 2026
Watson W. Mark
Director
Jul 16, 2026
AWARD39,400 sh

Earnings setup

Estimates
−$0.19
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.19–-$0.19No data$41.6M
Next QNoneNoneNo data$0.00
Current FY-$0.68-$0.68–-$0.68-1233.3%$118.6M
Next FY-$1.03-$1.03–-$1.03-51.5%$4.7M

Washington

Corporate Lobbying

7 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
2,417,496
shares short
+0.5%
vs prior settlement
4.0
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

21 filings · 2 press releases · 1 bullish · 3 bearish · 2 mixed · 15 neutral
All VXRT filing & press-release reports (23)